Top

Journal of Inflammation

Published in:

Open Access 01-12-2009 | Research

Stimulation with Peptidoglycan induces interleukin 6 and TLR2 expression and a concomitant downregulation of expression of adiponectin receptors 1 and 2 in 3T3-L1 adipocytes

Authors: Kolapo M Ajuwon, William Banz, Todd A Winters

Published in: Journal of Inflammation | Issue 1/2009

Abstract

Background

Inflammation is a major component of obesity and diabetes, and toll-like receptors (TLRs) play critical roles in the regulation of inflammation and response to pathogen associated molecular patterns (PAMPs) and fatty acids in. Although immune cells such as macrophages are primarily responsible for recognition and clearance of pathogens, adipocytes are also closely involved in the regulation of innate immunity and inflammation. Whereas it has been demonstrated that adipocytes respond to TLR4 stimulation with lipopolysacccharide, very little is known about their response to the TLR2 agonist, peptidoglycan.

Methods

We investigated the response to peptidoglycan from Staphylococcus aureus in differentiated 3T3-L1 adipocytes. Real-time PCR analysis was used to quantify the expression of interleukin 6 (IL6), adiponectin receptors (adipoR1 and adipoR2), toll-like receptor 2 (TLR2) and 4 (TLR2 4). Media level of IL6 was determined with ELISA.

Results

Adipocyte stimulation peptidoglycan induces IL6 expression (P < 0.01). Both siRNA mediated suppression of TLR2 and immunoneutralization of TLR2 with a TLR2 specific antibody inhibited response to peptidoglycan (P < 0.05). We also examined the regulation of TLR2 and TLR4 mRNA in peptidoglycan treated cells. Both peptidoglycan and lipopolysaccharide (LPS) robustly induce TLR2 mRNA expression, whereas TLR4 mRNA is weakly induced by LPS only (P < 0.05). Additionally, peptidoglycan downregulates the mRNA expression of adiponectin receptors, adipoR1 and adipoR2 (P < 0.05).

Conclusion

Obesity and type 2 diabetes are associated with increased expression of TLR2, this receptor could play a significant but previously unrecognized role in the establishment of chronic inflammation in adipose tissue in obesity.

Available only for authorised users

Ajuwon KM, Jacobi SK, Kuske JL, Spurlock ME: Interleukin-6 and interleukin-15 are selectively regulated by lipopolysaccharide and interferon-gamma in primary pig adipocytes. Am J Physiol Regul Integr Comp Physiol. 2004, 286: R547-R553.PubMedCrossRef

Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M, McIntosh MK: Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology. 2006, 147: 5340-5351. 10.1210/en.2006-0536.PubMedCrossRef

Pietsch J, Batra A, Stroh T, Fedke I, Glauben R, Okur B, Zeitz M, Siegmund B: Toll-like receptor expression and response to specific stimulation in adipocytes and preadipocytes: on the role of fat in inflammation. Ann N Y Acad Sci. 2006, 1072: 407-409. 10.1196/annals.1326.021.PubMedCrossRef

Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology. 2007, 132: 2169-2180. 10.1053/j.gastro.2007.03.059.PubMedCrossRef

Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE: The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem. 2000, 275: 24255-2463. 10.1074/jbc.M002137200.PubMedCrossRef

Ajuwon KM, Spurlock ME: Palmitate activates the NF-kappaB transcription factor and induces IL6 and TNF alpha expression in 3T3-L1 adipocytes. J Nutr. 2005, 135: 1841-1846.PubMed

Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Inves. 2006, 116: 3015-3025. 10.1172/JCI28898.CrossRef

Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007, 292: E740-E747. 10.1152/ajpendo.00302.2006.PubMedCrossRef

Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, Kumar S, McTernan PG: The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab. 2007, 92: 270-276. 10.1210/jc.2006-1151.PubMedCrossRef

10.

Murakami K, Bujo H, Unoki H, Saito Y: High fat intake induces a population of adipocytes to co-express TLR2 and TNFalpha in mice with insulin resistance. Biochem Biophys Res Commun. 2007, 354: 727-734. 10.1016/j.bbrc.2007.01.039.PubMedCrossRef

11.

Senn JJ: Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem. 2006, 281: 26865-26875. 10.1074/jbc.M513304200.PubMedCrossRef

12.

Sandor F, Buc M: Toll-like receptors. I. Structure, function and their ligands. Folia Biol (Praha). 2005, 51: 148-157.

13.

Hajjar AM, O'Mahony DS, Ozinsky A, Underhill DM, Aderem A, Klebanoff SJ, Wilson CB: Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol. 2001, 166: 15-19.PubMedCrossRef

14.

Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, Lodish HF, Ruderman NB: Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA. 2002, 99: 16309-16313. 10.1073/pnas.222657499.PubMedPubMedCentralCrossRef

15.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002, 8: 1288-1295. 10.1038/nm788.PubMedCrossRef

16.

Ajuwon KM, Spurlock ME: Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol. 2005, 288: R1220-1225.PubMedCrossRef

17.

Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME: Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun. 2004, 316: 924-929. 10.1016/j.bbrc.2004.02.130.PubMedCrossRef

18.

Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000, 102: 1296-1301.PubMedCrossRef

19.

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003, 423: 762-769. 10.1038/nature01705.PubMedCrossRef

20.

Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE: Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology. 2008, 149: 2270-2282. 10.1210/en.2007-1561.PubMedPubMedCentralCrossRef

21.

Liu Y, Michael MD, Kash S, Bensch WR, Monia BP, Murray SF, Otto KA, Syed SK, Bhanot S, Sloop KW, Sullivan JM, Reifel-Miller A: Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology. 2007, 148: 683-692. 10.1210/en.2006-0708.PubMedCrossRef

22.

Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T: Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004, 279: 30817-30822. 10.1074/jbc.M402367200.PubMedCrossRef

23.

Frost RA, Nystrom GJ, Lang CH: Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun-NH2-terminal kinase. Am J Physiol Regul Integr Comp Physiol. 2003, 285: R1153-R1164.PubMedCrossRef

24.

Takeda K, Akira S: Toll-like receptors in innate immunity. Int Immunol. 2005, 17: 1-14. 10.1093/intimm/dxh186.PubMedCrossRef

25.

Tanji T, Ip YT: Regulators of the Toll and Imd pathways in the Drosophila innate immune response. Trends Immunol. 2005, 26: 193-198. 10.1016/j.it.2005.02.006.PubMedCrossRef

26.

Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP: Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007, 92: 2272-2279. 10.1210/jc.2006-2545.PubMedCrossRef

27.

Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004, 92: 347-355. 10.1079/BJN20041213.PubMedCrossRef

28.

Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, Glass CK, Neels JG, Olefsky JM: A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 2007, 282: 35279-92. 10.1074/jbc.M706762200.PubMedCrossRef

29.

Wu L, Feng BS, He SH, Zheng PY, Croitoru K, Yang PC: Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: the role of TLR2 and NOD2. Immunol Cell Biol. 2007, 85: 538-545. 10.1038/sj.icb.7100079.PubMedCrossRef

30.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808.PubMedPubMedCentralCrossRef

31.

Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003, 112: 1821-1830.PubMedPubMedCentralCrossRef

32.

Berghe Vanden W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G: Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol. 2000, 60: 1185-1195. 10.1016/S0006-2952(00)00412-3.CrossRef

33.

Kawai T, Akira S: TLR signaling. Cell Death Differ. 2006, 13: 816-825. 10.1038/sj.cdd.4401850.PubMedCrossRef

34.

Akira S, Yamamoto M, Takeda K: Role of adapters in Toll-like receptor signalling. Biochem Soc Trans. 2003, 31: 637-642. 10.1042/BST0310637.PubMedCrossRef

35.

Matsuguchi T, Musikacharoen T, Ogawa T, Yoshikai Y: Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol. 2000, 165: 5767-5772.PubMedCrossRef

36.

Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takeya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y: Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Bio. 2007, 27: 1918-1925. 10.1161/ATVBAHA.106.136853.CrossRef

37.

Title: Stimulation with Peptidoglycan induces interleukin 6 and TLR2 expression and a concomitant downregulation of expression of adiponectin receptors 1 and 2 in 3T3-L1 adipocytes
Authors: Kolapo M Ajuwon
William Banz
Todd A Winters
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Journal of Inflammation / Issue 1/2009
Electronic ISSN: 1476-9255
DOI: https://doi.org/10.1186/1476-9255-6-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Role of TRPV3 in immune response to development of dermatitis

Is inflammation a consequence of extracellular hyperosmolarity?

Inflammatory markers in a 2-year soy intervention among premenopausal women

Gadolinium decreases inflammation related to myocardial ischemia and reperfusion injury

Hepcidin is elevated in mice injected with Mycoplasma arthritidis

Effects of hydrogen sulfide on inflammation in caerulein-induced acute pancreatitis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials